Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 8/20 | 0.37 |
| ▸ | MAOA | P21397 | 7/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173918 | 0.98 | NOS1 (0.50) | NOS1NOS2SLC18A3ALDH1A1GAA | |
| SCHEMBL8542775 | 0.98 | NOS1 (0.50) | NOS1NOS2SLC18A3ALDH1A1GAA | |
| SCHEMBL3115176 | 0.93 | NOS1 (0.48) | NOS1NOS2SLC18A3ALDH1A1GAA | |
| SCHEMBL4751341 | 0.93 | NOS1 (0.48) | NOS1NOS2SLC18A3ALDH1A1GAA | |
| SCHEMBL546334 | 0.93 | NOS1 (0.48) | NOS1NOS2SLC18A3ALDH1A1GAA | |
| SCHEMBL1749974 | 0.81 | NOS1 (0.44) | NOS1NOS2SLC18A3TAAR1MAOB | |
| SCHEMBL3559920 | 0.81 | CYP2C19 (0.38) | NOS1NOS2CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL6982998 | 0.79 | KDM1A (0.41) | NOS1NOS2ALDH1A1KDM1AMEN1 | |
| SCHEMBL3153900 | 0.79 | ALDH1A1 (0.37) | NOS1NOS2SLC18A3ALDH1A1KDM1A | |
| SCHEMBL4766448 | 0.79 | TAAR1 (0.41) | NOS1NOS2SLC18A3ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376447-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID PHARMA LTD (IN) | 2017-08-09 | — | — | EP | claimed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | claimed |
| US-8466145-B2 | Dipeptidyl peptidase IV inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-06-18 | — | — | US | claimed |
| US-8143275-B2 | Use of triazolopyrimidine derivatives as microbicides | LANXESS DEUTSCHLAND GMBH (DE) | 2012-03-27 | — | — | US | claimed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | claimed |
| EP-2379538-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-26 | — | — | EP | claimed |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | US | claimed |
| EP-2376447-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-19 | — | — | EP | claimed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| WO-2011058582-A1 | HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF FUNGAL INFECTIONS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-05-19 | — | — | WO | claimed |
| WO-1994014809-A1 | ANELLATED URACIL DERIVATES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-07-07 | — | — | WO | claimed |
| EP-0550113-A2 | Triazolopyrimidine derivatives with fungicidal activity | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1993-07-07 | — | — | EP | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| US-5151418-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-09-29 | — | — | US | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| US-5068231-A | Ureas and thioureas for relaxing muscles | A. H. ROBINS COMPANY INCORPORATED (US) | 1991-11-26 | — | — | US | claimed |
| EP-0345990-A2 | Polypeptide compounds | ZENECA LIMITED (GB) | 1989-12-13 | — | — | EP | claimed |
| EP-0003383-B1 | 4-AMINO-3-SULFONAMIDO PYRIDINE DERIVATIVES | A. CHRISTIAENS SOCIETE ANONYME (BE) | 1983-02-09 | — | — | EP | claimed |
| US-3946007-A | MICROBIOCIDES | THE DOW CHEMICAL COMPANY (US) | 1976-03-23 | — | — | US | claimed |
| US-3944525-A | Crosslinked resins prepared from an N,N'-bis-imide and a schiff base | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP7, DPP3 | NOS1 1212/4885NOS2 1116/4885SLC18A3 2706/4885 |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | NOS1 30/4885NOS2 48/4885SLC18A3 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.